Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Dexamethasone in CD20+ NHL
NCT00244855Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2004
- Primary completion
- Dec 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM) and 1 more (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Progression-free Survival at 6 months, Clinical Response Rate at 6 months and 1 more. Started May 2004; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)Waldenstrom macroglobulinemia (WM)cutaneous B-cell non-Hodgkin lymphoma (CBCL)
Beyond the preview
Go deeper on NCT00244855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244855.